Similar articles

• [The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione(suxibuzone), antiinflammatory drug. I. Plasma levels and urinary excretion after oral administration of suxibuzone (author's transl)].

  Shindo T, Yasuda Y, Taira K, Mitani N, Kanda A, Akazawa A. Shindo T, et al. Yakugaku Zasshi. 1979 Dec;99(12):1186-200. doi: 10.1248/yakushi1947.99.12_1186. Yakugaku Zasshi. 1979. PMID: 120893 Japanese. No abstract available.
• Comparison of the absorption, excretion, and metabolism of suxibuzone and phenylbutazone in humans.

  Yasuda Y, Shindo T, Mitani N, Ishida N, Oono F, Kageyama T. Yasuda Y, et al. J Pharm Sci. 1982 May;71(5):565-72. doi: 10.1002/jps.2600710521. J Pharm Sci. 1982. PMID: 7097505
• Absorption and distribution of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA2370) in the rat.

  Coppi G, Vidi A, Gallazzi A, Perego R. Coppi G, et al. Arzneimittelforschung. 1974 May;24(5):801-2. Arzneimittelforschung. 1974. PMID: 4408147 No abstract available.
• [The use of analgesic and antiphlogistic agents in small animals (author's transl)].

  Meutstege FJ. Meutstege FJ. Tijdschr Diergeneeskd. 1975 May 1;100(9):509-15. Tijdschr Diergeneeskd. 1975. PMID: 241131 Review. Dutch.
• Interaction of phenylbutazone and colchicine in binding to serum albumin in rheumatoid therapy: 1H NMR study.

  Maciazek-Jurczyk M, Sułkowska A, Bojko B, Równicka-Zubik J, Sułkowski WW. Maciazek-Jurczyk M, et al. Spectrochim Acta A Mol Biomol Spectrosc. 2009 Sep 15;74(1):1-9. doi: 10.1016/j.saa.2009.06.043. Epub 2009 Jun 25. Spectrochim Acta A Mol Biomol Spectrosc. 2009. PMID: 19615934 Review.